Seeking royalties, GSK expands mRNA patent litigation to include Modernas next-generation COVID shot
5.5
来源：
FiercePharma
发布时间：
2025-09-05 10:10
摘要：
GSK has expanded its patent litigation against Moderna to include the next-generation COVID-19 vaccine, mNexspike, claiming infringement of its mRNA technology patents. This legal action follows GSK's initial lawsuit regarding Moderna's Spikevax vaccine and highlights the ongoing complexities in mRNA patent disputes. The mNexspike vaccine recently received FDA approval based on phase 3 trial results, demonstrating improved efficacy compared to its predecessor.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+重点关注领域符合度
business_impact
1.0分+商业影响力
scientific_rigor
1.0分+数据支撑的科学性
timeliness_innovation
1.5分+时效性与创新性
investment_perspective
0.0分+BOCG投资视角
market_value_relevance
1.0分+市场价值相关性
team_institution_background
1.0分+团队与机构背景
technical_barrier_competition
0.0分+技术壁垒与竞争格局
关键证据
GSK's legal complaint centers on claims that it holds U.S. patents on lipid mRNA vaccine formulation technology.
The lawsuit alleges that Moderna's mNexspike vaccine uses the same composition and methods as GSK's patents.
GSK has previously sued Pfizer and BioNTech on similar grounds, indicating a broader trend in mRNA patent litigation.
真实性检查
否
AI评分总结
GSK has expanded its patent litigation against Moderna to include the next-generation COVID-19 vaccine, mNexspike, claiming infringement of its mRNA technology patents. This legal action follows GSK's initial lawsuit regarding Moderna's Spikevax vaccine and highlights the ongoing complexities in mRNA patent disputes. The mNexspike vaccine recently received FDA approval based on phase 3 trial results, demonstrating improved efficacy compared to its predecessor.